Biogen Inc (BIIB)

309.82
2.76 0.88
NASDAQ : Health Care
Prev Close 312.58
Open 311.70
Day Low/High 308.68 / 312.02
52 Wk Low/High 223.02 / 338.51
Volume 924.23K
Avg Volume 1.83M
Exchange NASDAQ
Shares Outstanding 219.12M
Market Cap 68.98B
EPS 15.40
P/E Ratio 22.23
Div & Yield N.A. (N.A)

Latest News

Perrigo Could Rake In $2.8 Billion in Tysabri Divestitures, Analysts Say

Perrigo Could Rake In $2.8 Billion in Tysabri Divestitures, Analysts Say

The company could divest non-core assets after Starboard Value revealed a 4.6% stake.

Applied Genetic Technologies Is an Attractive Acquisition Target for Allergan or Biogen

Applied Genetic Technologies Is an Attractive Acquisition Target for Allergan or Biogen

What to do with $40 billion? That is the question facing Allergan (AGN). One biotechnology stock which stands out as a potential target for Allergan is Applied Genetic Technologies (AGTC).

Apple's surprise

Apple's surprise

Apple's iPhone 7 launch has surprised the skeptics

New Data Presented At ECTRIMS Reinforce Efficacy Of ZINBRYTA™ (Daclizumab) And Support Long-Term Safety Profile

New Data Presented At ECTRIMS Reinforce Efficacy Of ZINBRYTA™ (Daclizumab) And Support Long-Term Safety Profile

A new post-hoc analysis from the pivotal DECIDE study shows that a significantly greater number of people treated with ZINBRYTA TM (daclizumab) achieved no evidence of disease activity (NEDA) compared to those taking...

Biogen To Report Third Quarter 2016 Financial Results On October 26, 2016

Biogen To Report Third Quarter 2016 Financial Results On October 26, 2016

Biogen Inc. (NASDAQ:BIIB) today announced it will report third quarter 2016 financial results on Wednesday, October 26, 2016, before the financial markets open.

Stocks Waver as Oil Tumbles but Apple Lifts Nasdaq

Stocks Waver as Oil Tumbles but Apple Lifts Nasdaq

Stocks lose highs by mid-afternoon Wednesday as a selloff in crude resumes.

Midday Report: Apple Rallies for Day Two; U.S. Stocks Climb After Extreme Three Days

Midday Report: Apple Rallies for Day Two; U.S. Stocks Climb After Extreme Three Days

U.S. stocks bounced around in the green in far more stable trading following three days of extreme swings.

Stocks Add to Gains as Apple Boosts Dow, Crude Fluctuates

Stocks Add to Gains as Apple Boosts Dow, Crude Fluctuates

Stocks add to slight gains on Wednesday as Wall Street stabilizes after three days of extreme swings.

Biogen (BIIB) Stock Gains on Positive Multiple Sclerosis Drug Data

Biogen (BIIB) Stock Gains on Positive Multiple Sclerosis Drug Data

Biogen (BIIB) reported Wednesday that Tecfidera, its multiple sclerosis treatment, had positive results in recent clinical and real world trials.

New Data Affirm Strong Efficacy And Well-Characterized Safety Profile Of TECFIDERA® In Both Clinical Studies And Real-World Setting

New Data Affirm Strong Efficacy And Well-Characterized Safety Profile Of TECFIDERA® In Both Clinical Studies And Real-World Setting

New real-world and clinical evidence demonstrates that TECFIDERA ® (dimethyl fumarate) consistently delivered strong, sustained efficacy in newly-diagnosed and previously treated patients with relapsing-remitting...

Biogen Demonstrates Commitment To Improving Patient Outcomes With Study On Burden Of MS And New Clinical Data From Its Leading MS Portfolio

Biogen Demonstrates Commitment To Improving Patient Outcomes With Study On Burden Of MS And New Clinical Data From Its Leading MS Portfolio

New research collected from more than 16,000 multiple sclerosis (MS) patients across Europe, in the largest study to capture the widespread impact of the disease, along with updated clinical findings from the company's...

Here's Why Investors Should Steer Clear of Opioids

Here's Why Investors Should Steer Clear of Opioids

Backed by the government, initiatives to develop and popularize non-opioid painkillers can make investors high on profits.

Biotech May Be About to Rescusitate

Biotech May Be About to Rescusitate

Check out this biotech ETF, and Biogen, for plays on any recovery.

Stocks Turn Mixed as Services Activity Sees Slowest Growth Since 2010

Stocks Turn Mixed as Services Activity Sees Slowest Growth Since 2010

Stocks hold mixed by mid-morning Tuesday after U.S. services activity last month declines more than expected.

Stock Futures Edge Higher as Wall Street Mulls Fed's Next Move

Stock Futures Edge Higher as Wall Street Mulls Fed's Next Move

Stock futures edge higher in the return from the long Labor Day weekend as markets continue to mull over the Federal Reserve's next big move.

Analysts' Actions -- Biogen, Gilead, CBS, VF Corp. and More

Analysts' Actions -- Biogen, Gilead, CBS, VF Corp. and More

Here are Tuesday's top research calls, including an upgrade for Gilead Sciences, downgrades for Biogen and VF Corp., and new coverage for CBS.

Biogen (BIIB) Stock Lower, Downgraded at Jefferies

Biogen (BIIB) Stock Lower, Downgraded at Jefferies

Biogen's (BIIB) stock rating was cut to 'hold' from 'buy' at Jefferies on Tuesday morning.

Is Biogen's Rough Ride Over?

Is Biogen's Rough Ride Over?

Biogen is up 2% year to date, and it would have been down more if not for a 40% move off the bottom.

Biogen (BIIB) Stock Climbs, Alzheimer's Treatment Gets Fast-Track Designation

Biogen (BIIB) Stock Climbs, Alzheimer's Treatment Gets Fast-Track Designation

Biogen (BIIB) stock was up Friday morning after the FDA fast-tracked its Alzheimer's drug.

Biogen's Investigational Alzheimer's Disease Treatment Aducanumab Granted FDA Fast Track Designation

Biogen's Investigational Alzheimer's Disease Treatment Aducanumab Granted FDA Fast Track Designation

Today Biogen (NASDAQ: BIIB) announced that aducanumab, its investigational treatment for early Alzheimer's disease (AD), was granted Fast Track designation by the U.

Biogen To Present At The Morgan Stanley Global Healthcare Conference

Biogen To Present At The Morgan Stanley Global Healthcare Conference

Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Morgan Stanley Global Healthcare Conference.

Nature Publishes Results From Pre-Clinical Research And Phase 1b Study Of Biogen's Investigational Alzheimer's Disease Treatment Aducanumab

Nature Publishes Results From Pre-Clinical Research And Phase 1b Study Of Biogen's Investigational Alzheimer's Disease Treatment Aducanumab

Results from pre-clinical research and PRIME, the Phase 1b study of Biogen's (NASDAQ: BIIB) investigational treatment for early Alzheimer's disease (AD), aducanumab, were published today in Nature.

Gilead Sinking Stock Price Calls Out for New Rescue Plan

Gilead Sinking Stock Price Calls Out for New Rescue Plan

Investors once OK with waiting patiently for a Gilead rebound are growing frustrated, even angry, at the company's lack of progress.

Biogen Is Setting Up for a Rare Low-Risk Buying Opportunity

Biogen Is Setting Up for a Rare Low-Risk Buying Opportunity

Biogen's pullback should drag shares lower into a low-risk buy zone.

Cramer: The Answer to This Market: Part 1

Cramer: The Answer to This Market: Part 1

The leadership is quite stark.

9 Stocks Smart Investors Put Their Money in Last Quarter

9 Stocks Smart Investors Put Their Money in Last Quarter

Hedge fund managers continue to flee stocks in the second quarter, but the smart money eyed several potential opportunities, including Charter Communications and Morgan Stanley.

Gilead May Be Better Off Splitting Itself in Two, Analysts Say

Gilead May Be Better Off Splitting Itself in Two, Analysts Say

A recent note from RBC Capital on Gilead gained a lot of attention as well as a pickup in call-option purchases.

Should Gilead Split in Two?

Should Gilead Split in Two?

RBC Capital analysts say this would free 'trapped value' on drug treatments.